Fennec Pharmaceuticals
FENC
96 hedge funds and large institutions have $120M invested in Fennec Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
14% more funds holding
Funds holding: 84 → 96 (+12)
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
4.17% less ownership
Funds ownership: 49.67% → 45.5% (-4.2%)
8% less capital invested
Capital invested by funds: $130M → $120M (-$10.1M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$7.39M |
| 2 |
AIC
AWM Investment Company
New York
|
+$5.84M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$4.41M |
| 4 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$3.06M |
| 5 |
ACA
Apis Capital Advisors
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
-$10.9M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.13M |
| 3 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
-$1.66M |
| 4 |
Jane Street
New York
|
-$399K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$175K |
FENC Hedge Fund Activity: Q4 2025 in Review
96 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2025, worth a combined $120M — down 7.8% from $130M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FENC positions and 8 closed out — a net gain of 12 holders — while 26 added to existing stakes and 24 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $7.39M. The largest seller was Southpoint Capital Advisors, cutting an estimated $10.9M.
- 96 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2025, up from 84 in Q3 2025.
- Funds reported $120M of Fennec Pharmaceuticals stock for Q4 2025, down 7.8% quarter-over-quarter.
- 20 funds opened new Fennec Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +12 holders.
- The largest Fennec Pharmaceuticals buyer in Q4 2025 was AIGH Capital Management, an estimated $7.39M added.
- The largest Fennec Pharmaceuticals seller in Q4 2025 was Southpoint Capital Advisors, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2025.